Adamis Pharmaceuticals Corp (NASDAQ:ADMP) shares traded down 14.3% on Thursday . The stock traded as low as $0.50 and last traded at $0.54, 2,470,913 shares were traded during trading. An increase of 387% from the average session volume of 507,394 shares. The stock had previously closed at $0.63.

Several equities research analysts recently weighed in on the stock. Maxim Group set a $6.00 price objective on shares of Adamis Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, August 9th. ValuEngine lowered shares of Adamis Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, September 4th. B. Riley upgraded shares of Adamis Pharmaceuticals from a “sell” rating to a “neutral” rating in a research note on Tuesday, July 23rd. Dawson James assumed coverage on shares of Adamis Pharmaceuticals in a research note on Tuesday, July 2nd. They set a “buy” rating on the stock. Finally, Zacks Investment Research lowered shares of Adamis Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $3.87.

The company has a quick ratio of 0.79, a current ratio of 1.04 and a debt-to-equity ratio of 0.05. The stock has a market cap of $39.00 million, a price-to-earnings ratio of -0.54 and a beta of 1.36. The firm’s 50 day moving average is $0.81 and its two-hundred day moving average is $1.37.

Adamis Pharmaceuticals (NASDAQ:ADMP) last posted its earnings results on Thursday, August 8th. The specialty pharmaceutical company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.03). The firm had revenue of $5.77 million during the quarter, compared to the consensus estimate of $5.82 million. Adamis Pharmaceuticals had a negative return on equity of 86.04% and a negative net margin of 205.32%. On average, analysts anticipate that Adamis Pharmaceuticals Corp will post -0.46 EPS for the current fiscal year.

Institutional investors have recently bought and sold shares of the company. GSA Capital Partners LLP bought a new position in shares of Adamis Pharmaceuticals in the second quarter valued at approximately $181,000. A.R.T. Advisors LLC boosted its holdings in shares of Adamis Pharmaceuticals by 143.8% in the second quarter. A.R.T. Advisors LLC now owns 61,711 shares of the specialty pharmaceutical company’s stock valued at $80,000 after acquiring an additional 36,400 shares in the last quarter. Morgan Stanley boosted its holdings in shares of Adamis Pharmaceuticals by 189.7% in the second quarter. Morgan Stanley now owns 757,124 shares of the specialty pharmaceutical company’s stock valued at $984,000 after acquiring an additional 495,793 shares in the last quarter. Vanguard Group Inc. boosted its holdings in shares of Adamis Pharmaceuticals by 4.5% in the second quarter. Vanguard Group Inc. now owns 1,791,266 shares of the specialty pharmaceutical company’s stock valued at $2,328,000 after acquiring an additional 77,498 shares in the last quarter. Finally, BlackRock Inc. boosted its holdings in shares of Adamis Pharmaceuticals by 1.5% in the second quarter. BlackRock Inc. now owns 962,687 shares of the specialty pharmaceutical company’s stock valued at $1,252,000 after acquiring an additional 14,312 shares in the last quarter. Institutional investors and hedge funds own 12.09% of the company’s stock.

Adamis Pharmaceuticals Company Profile (NASDAQ:ADMP)

Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company's specialty pharmaceutical product candidates comprise Symjepi (epinephrine) Injection pre-filled syringe (PFS) for use in the emergency treatment of acute allergic reactions, including anaphylaxis.

Recommended Story: Discover Your Risk Tolerance

Receive News & Ratings for Adamis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.